NASDAQ · SNTI
Senti Biosciences, Inc.
Healthcare · Biotechnology
$0.19▼ 1.10% ($0.00)at close
After hours$0.20▲ 5.15%7:40 PM ET
Valuation
Revenue & margin DCF
A cash-flow estimate wouldn't be reliable here
Every projected year produces negative free cash flow, so the model returns a negative enterprise value. A discounted-cash-flow valuation cannot be defended on those inputs, so it is not shown.
Only 4 of the five annual revenue periods are available; growth uses the observed fiscal-year spans. Annual revenue history contains a gap; multi-year changes are annualized over their actual fiscal-year span.
1 more note
Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.
Data notes
Only 4 of the five annual revenue periods are available; growth uses the observed fiscal-year spans. Annual revenue history contains a gap; multi-year changes are annualized over their actual fiscal-year span.
Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.
- 10-yr revenue CAGR
- 0.8%
- Ending operating margin
- 0.0%
- Discount rate
- 8.3%
USD · TTM ending Jun 30, 2026 · Price used $0.19 · Price Oct 23, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 90.58% over the last year. Free cash flow grew 21.87% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read changes if operating margin (currently -102,761.82%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Return analysis
Company profile
Senti Biosciences, Inc. is a pioneering company specializing in gene circuit technology.
Market multiples
Stock splits
Every 10 shares became 1
Profitability & growth
Analyst consensus
2
Buy
2
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Nov 12, 2026
Q3 FY26 · EPS est -$0.21 · Revenue est $15.9K
Q2 FY26
Reported Aug 14, 2026 · Latest
HoverTap a quarter to inspect
Actual
-$0.41
Estimate
-$0.27
Year over year
n/m
Vs prior quarter
n/m
1 beat · 3 misses in the last 4 quarters
Institutional Sentiment
Senti Biosciences, Inc. · SNTI
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.